Substance / Medication

Brexanolone

Overview

Active Ingredient
brexanolone
RxNorm CUI
2121777

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Brexanolone, zuranolone and related neurosteroid GABAreceptor positive allosteric modulators for postnatal depression.
Wilson Claire A, Robertson Lindsay, Ayre Karyn et al. · Cochrane Database Syst Rev · 2025
PMID: 40562419Meta-AnalysisFull text (PMC)
Brexanolone in Postpartum Depression:Analyses to Help Inform Clinical Decision-Making.
Gerbasi Margaret E, Meltzer-Brody Samantha, Acaster Sarah et al. · J Womens Health (Larchmt) · 2021
PMID: 33181049Meta-AnalysisFull text (PMC)
Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.
Zheng Wei, Cai Dong-Bin, Zheng Wei et al. · Psychiatry Res · 2019
PMID: 31323375Meta-Analysis
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
Meltzer-Brody Samantha, Colquhoun Helen, Riesenberg Robert et al. · Lancet · 2018
PMID: 30177236Trial
Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
Kanes Stephen J, Colquhoun Helen, Doherty James et al. · Hum Psychopharmacol · 2017
PMID: 28370307TrialFull text (PMC)
Brexanolone as adjunctive therapy in super-refractory status epilepticus.
Rosenthal Eric S, Claassen Jan, Wainwright Mark S et al. · Ann Neurol · 2017
PMID: 28779545TrialFull text (PMC)
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes Stephen, Colquhoun Helen, Gunduz-Bruce Handan et al. · Lancet · 2017
PMID: 28619476Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Brexanolone (substance)
SNOMED CT
787054008
UMLS CUI
C4548848
RxNorm CUI
2121777

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.